About changes of reimbursement for medicine
The Danish Health and Medicines Authority and the Reimbursement Committee regularly review public reimbursements for medicine. We assess whether medicines should be granted general reimbursement, reimbursement on special conditions (conditional reimbursement) or not be granted reimbursement at all.
One of the overall conditions that must be met in order for a medicinal product to get and maintain general reimbursement is that the therapeutic value must be reasonable relative to its price. This relationship can change over time, and the reimbursement status of medicines may change with it.
The reason for reassessing the reimbursement status of medicines
The primary objective of granting public reimbursement is to ensure that patients receive reimbursement for purchasing important medicine. But we must also ensure that public funds are used appropriately and encourage doctors to use medicine in a rational way, for instance by supporting equally effective treatment at a lower cost.
When we assess whether a medicine meets the conditions for reimbursement, we look at national and international treatment guides and compare their recommendations to the medicine prices.
Both treatment recommendations and medicine prices change over time - the latter often in connection with patent expiry. This may affect the assessment of what constitutes rational use of medicine within a given area of treatment - i.e. which medicine doctors should generally choose first.
For more information, please see:
Major reimbursement changes
Here you can read about current and previously implemented major changes of reimbursement for medicine:
- Changed reimbursement for medicines for depression and anxiety as of 5 March 2012
- The reimbursement for glucosamine is removed on 28 November 2011
- Change of the reimbursement for certain cardiovascular products as of 15 November 2010
- Changes in reimbursements for drugs for acid-related disorders as of 15 November 2010
- Changes in reimbursement for cardiovascular medicines as of 13 July 2009